By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001


SEARCH JOBS
Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.


Key Statistics


Email: contact@seagen.com
Ownership: Public

Web Site: Seattle Genetics
Employees:
Symbol: SGEN
 





Collaborations

Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 

MedImmune 





Company News
Seattle Genetics (SGEN) Highlights Promising Data With Tisotumab Vedotin In Cervical Cancer At ESMO 2017 Congress 9/8/2017 11:34:10 AM
Genmab A/S (GEN.CO) And Seattle Genetics (SGEN) To Co-Develop Tisotumab Vedotin For Solid Tumors 8/29/2017 6:25:04 AM
Seattle Genetics (SGEN) Release: FDA Accepts Supplemental Biologics License Application And Grants Priority Review For ADCETRIS (Brentuximab Vedotin) In Cutaneous T-Cell Lymphoma 8/16/2017 6:49:48 AM
Seattle Genetics (SGEN) Nabs Bristol-Myers Squibb (BMY)’s Bothell MFG Facility, Plans to Offer Jobs to Current Employees 8/2/2017 6:13:53 AM
Seattle Genetics (SGEN) Reports Second Quarter 2017 Financial Results 7/28/2017 6:34:47 AM
Seattle Genetics (SGEN) Release: Health Canada Approves ADCETRIS (Brentuximab Vedotin) For The Post-ASCT Consolidation Treatment Of Patients With Hodgkin Lymphoma At Increased Risk Of Relapse Or Progression 7/25/2017 8:02:48 AM
Seattle Genetics (SGEN) Announces Clinical Collaboration To Expand The Therapeutic Evaluation Of SGN-LIV1A In Triple Negative Breast Cancer 7/24/2017 7:41:19 AM
Seattle Genetics (SGEN) To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 27, 2017 7/6/2017 9:47:19 AM
Investors Relieved as Seattle Genetics (SGEN) Pulls Out Win for Phase III Lymphoma Trial 6/26/2017 5:39:11 AM
Seattle Genetics (SGEN) Takes Another Hit as the FDA Slaps Hold on IND for Vadastuximab Talirine 6/22/2017 5:48:06 AM
12345678910...
//-->